FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154915517> ?p ?o ?g. }

• W2154915517 endingPage "457" @default.
• W2154915517 startingPage "448" @default.
• W2154915517 abstract "BackgroundThe clinical benefits of glucose–insulin–potassium (GIK) and tight glycaemic control in patients undergoing coronary artery bypass grafting (CABG) may be partly explained by an anti-inflammatory effect. We applied GIK as a hyperinsulinaemic normoglycaemic clamp for >25 h and quantified its effect on systemic inflammation in patients undergoing CABG.MethodsData obtained in 21 non-diabetic patients with normal left ventricular function scheduled for elective coronary artery surgery, who were randomly allocated to a control or GIK group, were analysed. In GIK patients, regular insulin was infused at a fixed rate of 0.1 IU kg−1 h−1. The infusion rate of glucose (30%) was adjusted to maintain blood glucose levels within a target range of 4.0–5.5 mmol litre−1. Plasma concentrations of interleukins 6, 8 and 10, C-reactive protein (CRP) and serum amyloid A (SAA) were measured on the day of surgery and on the first and second postoperative days (POD1 and POD2).ResultsIn the GIK group hypoglycaemia (glucose <2.2 mmol litre−1) did not occur, whereas hyperglycemia (glucose >6.1 mmol litre−1) developed in 15% of all measurements. In control patients, hyperglycaemia developed in >80% of all measurements in the presence of low endogenous insulin levels. CRP and SAA levels increased in both groups, with maximum levels measured on POD2. GIK treatment significantly reduced CRP and SAA levels. Interleukin levels increased significantly in both groups following cardiopulmonary bypass, but no differences were found between the groups.ConclusionHyperinsulinaemic normoglycaemic clamp is an effective method of maintaining tight glycaemic control in patients undergoing CABG and it attenuates the systemic inflammatory response in these patients. This effect may partly contribute to the reported beneficial effect of glycaemic control in patients undergoing CABG. The clinical benefits of glucose–insulin–potassium (GIK) and tight glycaemic control in patients undergoing coronary artery bypass grafting (CABG) may be partly explained by an anti-inflammatory effect. We applied GIK as a hyperinsulinaemic normoglycaemic clamp for >25 h and quantified its effect on systemic inflammation in patients undergoing CABG. Data obtained in 21 non-diabetic patients with normal left ventricular function scheduled for elective coronary artery surgery, who were randomly allocated to a control or GIK group, were analysed. In GIK patients, regular insulin was infused at a fixed rate of 0.1 IU kg−1 h−1. The infusion rate of glucose (30%) was adjusted to maintain blood glucose levels within a target range of 4.0–5.5 mmol litre−1. Plasma concentrations of interleukins 6, 8 and 10, C-reactive protein (CRP) and serum amyloid A (SAA) were measured on the day of surgery and on the first and second postoperative days (POD1 and POD2). In the GIK group hypoglycaemia (glucose <2.2 mmol litre−1) did not occur, whereas hyperglycemia (glucose >6.1 mmol litre−1) developed in 15% of all measurements. In control patients, hyperglycaemia developed in >80% of all measurements in the presence of low endogenous insulin levels. CRP and SAA levels increased in both groups, with maximum levels measured on POD2. GIK treatment significantly reduced CRP and SAA levels. Interleukin levels increased significantly in both groups following cardiopulmonary bypass, but no differences were found between the groups. Hyperinsulinaemic normoglycaemic clamp is an effective method of maintaining tight glycaemic control in patients undergoing CABG and it attenuates the systemic inflammatory response in these patients. This effect may partly contribute to the reported beneficial effect of glycaemic control in patients undergoing CABG." @default.
• W2154915517 created "2016-06-24" @default.
• W2154915517 creator A5002897147 @default.
• W2154915517 creator A5010292778 @default.
• W2154915517 creator A5032072489 @default.
• W2154915517 creator A5040740846 @default.
• W2154915517 creator A5050776175 @default.
• W2154915517 creator A5068855118 @default.
• W2154915517 creator A5075584588 @default.
• W2154915517 date "2005-10-01" @default.
• W2154915517 modified "2023-10-14" @default.
• W2154915517 title "Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: effects on inflammatory response during coronary artery surgery" @default.
• W2154915517 cites W124335555 @default.
• W2154915517 cites W1964532167 @default.
• W2154915517 cites W1980717583 @default.
• W2154915517 cites W1981569438 @default.
• W2154915517 cites W1992182022 @default.
• W2154915517 cites W1998935245 @default.
• W2154915517 cites W2000011436 @default.
• W2154915517 cites W2005636700 @default.
• W2154915517 cites W2008545806 @default.
• W2154915517 cites W2010346254 @default.
• W2154915517 cites W2014047689 @default.
• W2154915517 cites W2017765829 @default.
• W2154915517 cites W2029651486 @default.
• W2154915517 cites W2031350146 @default.
• W2154915517 cites W2036922676 @default.
• W2154915517 cites W2037498580 @default.
• W2154915517 cites W2041339005 @default.
• W2154915517 cites W2045658220 @default.
• W2154915517 cites W2046874354 @default.
• W2154915517 cites W2052806765 @default.
• W2154915517 cites W2054900587 @default.
• W2154915517 cites W2056371421 @default.
• W2154915517 cites W2056950265 @default.
• W2154915517 cites W2074718394 @default.
• W2154915517 cites W2074745934 @default.
• W2154915517 cites W2074773055 @default.
• W2154915517 cites W2088215178 @default.
• W2154915517 cites W2090483218 @default.
• W2154915517 cites W2105866978 @default.
• W2154915517 cites W2111349683 @default.
• W2154915517 cites W2120795994 @default.
• W2154915517 cites W2123560318 @default.
• W2154915517 cites W2129324312 @default.
• W2154915517 cites W2133691474 @default.
• W2154915517 cites W2140671916 @default.
• W2154915517 cites W2151169124 @default.
• W2154915517 cites W2152990151 @default.
• W2154915517 cites W2155518237 @default.
• W2154915517 cites W2163567504 @default.
• W2154915517 cites W2255062718 @default.
• W2154915517 cites W3143169386 @default.
• W2154915517 cites W4232045253 @default.
• W2154915517 cites W939544876 @default.
• W2154915517 doi "https://doi.org/10.1093/bja/aei220" @default.
• W2154915517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16100235" @default.
• W2154915517 hasPublicationYear "2005" @default.
• W2154915517 type Work @default.
• W2154915517 sameAs 2154915517 @default.
• W2154915517 citedByCount "90" @default.
• W2154915517 countsByYear W21549155172012 @default.
• W2154915517 countsByYear W21549155172013 @default.
• W2154915517 countsByYear W21549155172014 @default.
• W2154915517 countsByYear W21549155172015 @default.
• W2154915517 countsByYear W21549155172017 @default.
• W2154915517 countsByYear W21549155172019 @default.
• W2154915517 countsByYear W21549155172020 @default.
• W2154915517 countsByYear W21549155172022 @default.
• W2154915517 crossrefType "journal-article" @default.
• W2154915517 hasAuthorship W2154915517A5002897147 @default.
• W2154915517 hasAuthorship W2154915517A5010292778 @default.
• W2154915517 hasAuthorship W2154915517A5032072489 @default.
• W2154915517 hasAuthorship W2154915517A5040740846 @default.
• W2154915517 hasAuthorship W2154915517A5050776175 @default.
• W2154915517 hasAuthorship W2154915517A5068855118 @default.
• W2154915517 hasAuthorship W2154915517A5075584588 @default.
• W2154915517 hasBestOaLocation W21549155171 @default.
• W2154915517 hasConcept C126322002 @default.
• W2154915517 hasConcept C134018914 @default.
• W2154915517 hasConcept C164705383 @default.
• W2154915517 hasConcept C176674119 @default.
• W2154915517 hasConcept C2776820930 @default.
• W2154915517 hasConcept C2777391703 @default.
• W2154915517 hasConcept C2778808658 @default.
• W2154915517 hasConcept C2778881276 @default.
• W2154915517 hasConcept C2779306644 @default.
• W2154915517 hasConcept C2780352109 @default.
• W2154915517 hasConcept C2780988686 @default.
• W2154915517 hasConcept C31174226 @default.
• W2154915517 hasConcept C42219234 @default.
• W2154915517 hasConcept C71924100 @default.
• W2154915517 hasConceptScore W2154915517C126322002 @default.
• W2154915517 hasConceptScore W2154915517C134018914 @default.
• W2154915517 hasConceptScore W2154915517C164705383 @default.
• W2154915517 hasConceptScore W2154915517C176674119 @default.
• W2154915517 hasConceptScore W2154915517C2776820930 @default.
• W2154915517 hasConceptScore W2154915517C2777391703 @default.

• next